drugset / Trial / NCT06389123
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
Phase 1
Recruiting
40 enrolled
University of California, Davis
National Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I study to evaluate the safety and efficacy of the \[68Ga\]Ga DOTA-5G and \[177Lu\]Lu DOTA-ABM-5G theranostics pair in patients with metastatic cancer.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2029-07-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | [177Lu]Lu DOTA-ABM-5G | Unknown | — | — |
| Subject | [68Ga]Ga DOTA-5G | Diagnostic / imaging agent | — | — |